PRESS RELEASE published on 01/29/2025 at 15:42, 2 months 12 days ago Inside Information / Other news releases UZEDY® sales reach $117M in 2024, surpassing Teva's expectations. Medincell poised for $160M in 2025 with Olanzapine Long-Acting Injectable near launch. Key partnership and financial insights Sales Partnership Medincell Teva Pharmaceuticals UZEDY®
BRIEF published on 12/12/2024 at 21:35, 3 months 29 days ago Medincell Joins Euronext SBF 120 Index Market Capitalization Medincell CAC 40 Euronext SBF 120 Financial Visibility
PRESS RELEASE published on 12/12/2024 at 21:30, 3 months 29 days ago Inside Information / Other news releases Medincell joins Euronext SBF 120 & CAC Mid 60 indices, enhancing visibility and investor appeal. Market capitalization-based indices by Euronext. Effective inclusion from Dec 20 Market Capitalization Medincell Index Inclusion Euronext SBF 120 CAC Mid 60
BRIEF published on 11/28/2024 at 18:45, 4 months 12 days ago Medincell Announces Video Conference for Half-Year Results Half-year Results Schizophrenia Medincell Videoconference BEPO Technology
BRIEF published on 11/22/2024 at 18:05, 4 months 18 days ago MedinCell: Update of share capital and voting rights Share Capital Voting Rights Euronext Actions Medincell
BRIEF published on 11/06/2024 at 13:47, 5 months 4 days ago Medincell: 2024 revenues on the rise and significant clinical progress Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 5 months 4 days ago Inside Information / Other news releases Medincell achieves 25% increase in 2024 UZEDY® revenue outlook reaching $100M and key milestone in Olanzapine LAI Phase 3 clinical trials. Teva Pharmaceuticals shares Q3 results Revenue Clinical Trials Medincell Teva Pharmaceuticals UZEDY
BRIEF published on 10/01/2024 at 15:47, 6 months 9 days ago Threshold crossing by Mirova in MEDINCELL Capital Actions Threshold Crossing Medincell Mirova
BRIEF published on 09/24/2024 at 11:54, 6 months 16 days ago Teva and Medincell Present Promising Results on Olanzapine LAI for Schizophrenia Clinical Trial Schizophrenia Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/24/2024 at 11:53, 6 months 16 days ago Inside Information / Other news releases Teva and Medincell reveal positive efficacy, safety, and tolerability data from Phase 3 study on Olanzapine LAI for schizophrenia treatment, presenting at ECNP 2024 Schizophrenia Treatment Phase 3 Study Medincell Teva Olanzapine LAI
Published on 04/11/2025 at 00:00, 18 minutes ago Onco-Innovations’ Inka Health Publishes Roche-Sponsored Study Advancing Real-World Oncology Research
Published on 04/10/2025 at 23:00, 1 hour 18 minutes ago Highlander Silver Receives Conditional Approval to List on the TSX, Files Base Shelf Prospectus and Establishes ATM Program as Longer Term Financial Alternatives
Published on 04/10/2025 at 22:15, 2 hours 3 minutes ago Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program
Published on 04/10/2025 at 22:15, 2 hours 3 minutes ago SWK Holdings Announces Closing of Royalty Sale and $4.00 Per Share Special Dividend
Published on 04/10/2025 at 20:47, 3 hours 31 minutes ago EQS-Adhoc: Hinkel & Cie. GmbH: first creditors´meeting of the bond DE000A2AAPX4
Published on 04/10/2025 at 20:44, 3 hours 34 minutes ago EQS-Adhoc: artnet AG: artnet is in talks with two investors regarding a potential takeover offer
Published on 04/10/2025 at 19:00, 5 hours 18 minutes ago Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Published on 04/10/2025 at 18:57, 5 hours 21 minutes ago EQS-Adhoc: HAMBORNER REIT AG: Adjustment of dividend strategy
Published on 04/10/2025 at 17:45, 6 hours 33 minutes ago EURAZEO INVESTS IN EKOSCAN INTEGRITY, A LEADING GLOBAL PROVIDER OF ADVANCED NON-DESTRUCTIVE TESTING SOLUTIONS FOR CRITICAL INDUSTRIAL APPLICATIONS AND INFRASTRUCTURE
Published on 04/09/2025 at 18:59, 1 day 5 hours ago Description of the 2025-2026 Share Buyback Program
Published on 04/09/2025 at 18:57, 1 day 5 hours ago Minutes of the Combined General Meeting held on April 9, 2025
Published on 04/09/2025 at 17:45, 1 day 6 hours ago COGELEC : 2024 full-year results and Q1 2025 revenue.
